AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy (AYU-STEP)
Effect of AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy: Prospective Pilot Study
Chemotherapy-induced peripheral neuropathy (CIPN) affects approximately 40% of patients treated with taxanes. These agents may cause burning pain, paresthesia, numbness, and loss of proprioceptive sensitivity, which can reduce well-being and impair quality of life.In this context, implementing non-pharmacological interventions, such as foot treatment/manipulation proposed in this project, represents a promising area to explore complementary therapies with minimal toxicity and low cost for symptom management.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Irene Feroce
- 電話番号:+39 0257489551
- メール:irene.feroce@ieo.it
研究場所
-
-
-
Milan、イタリア、20141
- 募集
- European Institute of Oncology
-
コンタクト:
- Irene Feroce
- 電話番号:0257489551
- メール:irene.feroce@ieo.it
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 18 anni
- Diagnosis of carcinoma with ongoing treatment or treatment completed within the previous 6 months with taxanes (paclitaxel/docetaxel).
- Grade 1-2 sensory-motor peripheral neuropathy (NCI-CTCAE v5).
- Able to walk independently.
- Written informed consent.
Exclusion Criteria:
- Pre-existing diabetic neuropathy
- Foot ulcers or infections
- Central neurological disorders
- Concomitant specific treatment for CINP including other complementary medicine. Occasional over the counter drugs such as NSIDs or pain killer are allowed. Any other clinical condition that, at the discretion of the physician or practitioner, may contraindicate participation in the study procedures.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Treatment arm
Manual manipulation of the feet |
The treatment consists of manual manipulation of the feet using Mahanarayan oil. Each session lasts approximately 30-40 minutes and is performed with the patient in a supine position, including massage of the foot and lower leg. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of patients that completed the treatment
時間枠:From enrollment to the follow-up contact at 10 weeks
|
Adherence to treatment will be measured as the number of subjects that completed all study treatment sessions on the total number of subjects enrolled. |
From enrollment to the follow-up contact at 10 weeks
|
|
Incidence of local adverse events related to the use of medicated oils during treatement sessions or manual therapy.
時間枠:From enrollment to the follow-up contact at 10 weeks
|
Incidence will be calculated as the number of local adverse events related to the use of medicated oils during treatement sessions or manual therapy on the total number of treatment sessions administered. |
From enrollment to the follow-up contact at 10 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in the score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale (QLQ-CIPN20) at 10 weeks.
時間枠:From enrollment to the follow-up contact at 10 weeks
|
Impact of treatment on Chemotherapy-induced peripheral neuropathy (CIPN) will be assessed using the QLQ-CIPN20 questionnaire. The QLQ-CIPN20 questionnaire will be administered four times: before the first treatment, at mid-treatment, at the end of treatment, and at follow-up. Higher the resulting score mean higher the CIPN affect the patient. Impact of treatment will be defined by the comparison of initial scoring and post treatment scoring. |
From enrollment to the follow-up contact at 10 weeks
|
|
Change from baseline in the score of The McGill Pain Questionnaire (P.R.I.) at 10 weeks.
時間枠:From enrollment to the follow-up contact at 10 weeks
|
The McGill Pain Questionnaire (P.R.I.) will be administered before the first treatment, at the end of the treatment, and at follow-up. Higher the resulting score mean higher the paint felt by the patient. Impact of treatment on the reduction of the pain will be defined by the comparison of initial scoring and post treatment scoring. |
From enrollment to the follow-up contact at 10 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- UID 5323
- L2-657 (その他の識別子:Comitato Etico Lombardia 2)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。